Yanan Zhu
Stock Analyst at Wells Fargo
(4.55)
# 987
Out of 4,574 analysts
422
Total ratings
36.2%
Success rate
15.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Initiated Coverage: Buy | $55 | $34.17 | +60.96% | 1 | Jul 15, 2026 | |
| RNA Atrium Therapeutics | Maintained: Buy | $25 | $11.49 | +117.58% | 2 | Jul 15, 2026 | |
| IONS Ionis Pharmaceuticals | Rated: Buy | $100 | $56.55 | +76.83% | 44 | Jul 10, 2026 | |
| SGMOQ Sangamo Therapeutics, Inc. | Rated: Hold | n/a | $0.065 | - | 22 | Jun 25, 2026 | |
| ENGN enGene Therapeutics | Rated: Hold | $2 | $1.82 | +9.89% | 18 | Jun 15, 2026 | |
| BEAM Beam Therapeutics | Maintained: Buy | $70 | $25.10 | +178.88% | 22 | Jun 4, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Hold | $15 | $10.73 | +39.79% | 26 | May 12, 2026 | |
| MGX Metagenomi Therapeutics | Maintained: Buy | $12 → $9 | $1.21 | +646.89% | 14 | May 11, 2026 | |
| CYTK Cytokinetics | Maintained: Buy | $95 → $105 | $80.74 | +30.05% | 2 | May 7, 2026 | |
| SRPT Sarepta Therapeutics | Maintained: Buy | $38 | $15.68 | +142.35% | 15 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $400 | $325.90 | +22.74% | 2 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $5.52 | +99.28% | 28 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $75 | $46.54 | +61.15% | 15 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $50 → $90 | $102.13 | -11.88% | 14 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $29.64 | +51.82% | 4 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $2.60 | +53.85% | 25 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $15 → $60 | $38.97 | +53.96% | 27 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $5.53 | +261.66% | 26 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $4.99 | +180.56% | 27 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $1.45 | +244.83% | 19 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $2.84 | +40.85% | 9 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2.5 | $2.41 | +3.73% | 12 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $11 → $0.1 | $0.0001 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 → $1 | $0.0292 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.10 | n/a | 13 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $30.37 | n/a | 7 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $45 → $30 | $1.94 | n/a | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $272 → $326 | $918.22 | n/a | 4 | Feb 2, 2021 |
Pharvaris
Jul 15, 2026
Initiated Coverage: Buy
Price Target: $55
Current: $34.17
Upside: +60.96%
Atrium Therapeutics
Jul 15, 2026
Maintained: Buy
Price Target: $25
Current: $11.49
Upside: +117.58%
Ionis Pharmaceuticals
Jul 10, 2026
Rated: Buy
Price Target: $100
Current: $56.55
Upside: +76.83%
Sangamo Therapeutics, Inc.
Jun 25, 2026
Rated: Hold
Price Target: n/a
Current: $0.065
Upside: -
enGene Therapeutics
Jun 15, 2026
Rated: Hold
Price Target: $2
Current: $1.82
Upside: +9.89%
Beam Therapeutics
Jun 4, 2026
Maintained: Buy
Price Target: $70
Current: $25.10
Upside: +178.88%
Intellia Therapeutics
May 12, 2026
Maintained: Hold
Price Target: $15
Current: $10.73
Upside: +39.79%
Metagenomi Therapeutics
May 11, 2026
Maintained: Buy
Price Target: $12 → $9
Current: $1.21
Upside: +646.89%
Cytokinetics
May 7, 2026
Maintained: Buy
Price Target: $95 → $105
Current: $80.74
Upside: +30.05%
Sarepta Therapeutics
May 7, 2026
Maintained: Buy
Price Target: $38
Current: $15.68
Upside: +142.35%
May 7, 2026
Maintained: Buy
Price Target: $400
Current: $325.90
Upside: +22.74%
May 7, 2026
Maintained: Buy
Price Target: $11
Current: $5.52
Upside: +99.28%
May 5, 2026
Maintained: Hold
Price Target: $75
Current: $46.54
Upside: +61.15%
Apr 14, 2026
Rated: Buy
Price Target: $50 → $90
Current: $102.13
Upside: -11.88%
Apr 2, 2026
Maintained: Buy
Price Target: $45
Current: $29.64
Upside: +51.82%
Mar 10, 2026
Maintained: Hold
Price Target: $4
Current: $2.60
Upside: +53.85%
Mar 9, 2026
Upgraded: Buy
Price Target: $15 → $60
Current: $38.97
Upside: +53.96%
Mar 4, 2026
Maintained: Buy
Price Target: $20
Current: $5.53
Upside: +261.66%
Feb 25, 2026
Reiterated: Buy
Price Target: $14
Current: $4.99
Upside: +180.56%
Jan 14, 2026
Maintained: Buy
Price Target: $5
Current: $1.45
Upside: +244.83%
Jan 13, 2026
Maintained: Hold
Price Target: $4
Current: $2.84
Upside: +40.85%
Jan 5, 2026
Maintained: Hold
Price Target: $2.5
Current: $2.41
Upside: +3.73%
May 14, 2025
Downgraded: Hold
Price Target: $11 → $0.1
Current: $0.0001
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: $1.5 → $1
Current: $0.0292
Upside: n/a
May 6, 2025
Maintained: Buy
Price Target: $10
Current: $3.10
Upside: n/a
May 16, 2024
Rated: Hold
Price Target: n/a
Current: $30.37
Upside: n/a
Aug 16, 2023
Maintained: Hold
Price Target: $45 → $30
Current: $1.94
Upside: n/a
Feb 2, 2021
Maintained: Hold
Price Target: $272 → $326
Current: $918.22
Upside: n/a